Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) – Pipeline Review, H1 2018’, provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Infectious Disease under development targeting Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)

– The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aduro BioTech Inc

Agenus Inc

Alligator Bioscience AB

Bristol-Myers Squibb Co

Cold Genesys Inc

Crown Bioscience Inc

Five Prime Therapeutics Inc

GigaGen Inc

Immunocore Ltd

Immunwork Inc

Innovent Biologics Inc

JHL Biotech Inc

MacroGenics Inc

MedImmune LLC

Merck & Co Inc

OncoImmune Inc

PharmAbcine Inc

Premier Biomedical Inc

Replimune Ltd

Serometrix LLC

Sutro Biopharma Inc

Tikcro Technologies Ltd

Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Overview

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Companies Involved in Therapeutics Development

Aduro BioTech Inc

Agenus Inc

Alligator Bioscience AB

Bristol-Myers Squibb Co

Cold Genesys Inc

Crown Bioscience Inc

Five Prime Therapeutics Inc

GigaGen Inc

Immunocore Ltd

Immunwork Inc

Innovent Biologics Inc

JHL Biotech Inc

MacroGenics Inc

MedImmune LLC

Merck & Co Inc

OncoImmune Inc

PharmAbcine Inc

Premier Biomedical Inc

Replimune Ltd

Serometrix LLC

Sutro Biopharma Inc

Tikcro Technologies Ltd

Xencor Inc

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drug Profiles

10B-10 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADU-1604 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGEN-1884 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGEN-2041 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit CTLA4 for Melanoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATOR-1015 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Antagonize CTLA4 for Solid Tumor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Antagonize CTLA-4 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Inhibit PD L1 and CTLA4 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986218 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986249 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-0070 + Immune Checkpoint Modulator Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-0161 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNC-225 + CNC-118 + Anti-CTLA-4 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-1002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + IMCgp-100 + tremelimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + tremelimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPT-155 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBI-310 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JMW-3B3 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KN-044 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-3617 + tremelimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGD-019 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1308 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize 1 PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize CTLA-4 for Metastatic Melanoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize CTLA-4 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize CTLA4 for Solid Tumors Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONC-392 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize CTLA4 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CTLA4 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tavolimab + tremelimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-1254 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tremelimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-20717 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-22841 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Dormant Products

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Discontinued Products

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Product Development Milestones

Featured News & Press Releases

Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015

Jan 22, 2018: European Commission Approves Bristol-Myers Squibb's Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Jan 22, 2018: Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

Jan 20, 2018: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer

Dec 29, 2017: CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia

Dec 18, 2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Dec 15, 2017: CHMP Adopts Positive Opinion for Yervoy

Dec 13, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review

Nov 28, 2017: CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic

Nov 28, 2017: European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma

Nov 10, 2017: Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604

Nov 10, 2017: MacroGenics To Present Poster on MGD019 at 32nd Annual SITC Meeting 2017

Nov 09, 2017: Agenus To Present on Lead Antibody Program AGEN1884 (CTLA-4) at SITC 2017

Nov 08, 2017: Xencor Presents Preclinical Data on Tumor Microenvironment Targeting Bispecific XmAb20717 At Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

Nov 07, 2017: Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aduro BioTech Inc, H1 2018

Pipeline by Agenus Inc, H1 2018

Pipeline by Alligator Bioscience AB, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Cold Genesys Inc, H1 2018

Pipeline by Crown Bioscience Inc, H1 2018

Pipeline by Five Prime Therapeutics Inc, H1 2018

Pipeline by GigaGen Inc, H1 2018

Pipeline by Immunocore Ltd, H1 2018

Pipeline by Immunwork Inc, H1 2018

Pipeline by Innovent Biologics Inc, H1 2018

Pipeline by JHL Biotech Inc, H1 2018

Pipeline by MacroGenics Inc, H1 2018

Pipeline by MedImmune LLC, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by OncoImmune Inc, H1 2018

Pipeline by PharmAbcine Inc, H1 2018

Pipeline by Premier Biomedical Inc, H1 2018

Pipeline by Replimune Ltd, H1 2018

Pipeline by Serometrix LLC, H1 2018

Pipeline by Sutro Biopharma Inc, H1 2018

Pipeline by Tikcro Technologies Ltd, H1 2018

Pipeline by Xencor Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports